APPLICATIONS OF TECHNOLOGY:
- Therapies for acute and/or chronic intestinal diseases
- Genetic diagnosis
- Gene regulatory sequencing active in developing gastro intestine
- Enables identification of patients for specific treatment
Berkeley Lab researchers have identified a novel human gene that when mutated leads to symptoms of severe, intractable, and congenital newborn diarrhea – a life-threatening disorder. In addition, the researchers identified a gene regulatory sequence driving the expression of this gene in a gastrointestinal-specific manner.
The Berkeley Lab research suggests this protein as a target for drug discovery or a therapeutic protein to treat varieties of acute or chronic intestinal diseases such as severe infant diarrhea, irritable bowel syndrome, Crohn’s, or other gastrointestinal diseases.
DEVELOPMENT STAGE: Proven principle
STATUS: Patent pending. Available for licensing or collaborative research.